Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Alejandro Rodriguez-Garcia, Alejandro Babayan-Sosa, Arturo Ramirez-Miranda, Concepcion Santa Cruz-Valdes, Everardo Hernandez-Quintela, Julio C Hernandez-Camarena, Nallely Ramos-Betancourt, Regina Velasco-Ramos & Raul E Ruiz-Lozano. (2022) A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel. Clinical Ophthalmology 16, pages 1331-1355.
Read now
Read now
Wenyan Peng, Xiuying Jiang, Lei Zhu, Xiaofeng Li, Qizhi Zhou, Ying Jie, Zhipeng You, Miaoqin Wu, Xiuming Jin, Xiaoyi Li & Shiyou Zhou. (2022) Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial. Drug Design, Development and Therapy 16, pages 3183-3194.
Read now
Read now
Laura M Periman, Francis S Mah & Paul M Karpecki. (2020) A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments. Clinical Ophthalmology 14, pages 4187-4200.
Read now
Read now
Articles from other publishers (14)
Elisabeth M Messmer, Sajjad Ahmad, José M Benitez del Castillo, Ewa Mrukwa-Kominek, Maurizio Rolando, Oksana Vitovska & Christophe Baudouin. (2022) Management of inflammation in dry eye disease: Recommendations from a European panel of experts. European Journal of Ophthalmology 33:3, pages 1294-1307.
Crossref
Crossref
Desti Priani, Habibah S. Muhiddin, Junaedi Sirajuddin, Hasnah B. Eka, Burhanuddin Bahar & Agussalim Bukhari. (2023) Effectiveness of Topical Cyclosporin-A 0.1% Compared to Combined Topical Cyclosporin-A 0.1% with Topical Sodium Hyaluronate on Interleukin-6 Levels in the Tears of Patients with Dry Eye Disease. Vision 7:2, pages 31.
Crossref
Crossref
Ka-Ying Wong, Yibo Liu, Liping Zhou, Man-Sau Wong & Juewen Liu. (2023) Mucin-targeting-aptamer functionalized liposomes for delivery of cyclosporin A for dry eye diseases. Journal of Materials Chemistry B.
Crossref
Crossref
Sanaz Sadig Baheran, Raid G. Alany, Sianne Schwikkard, Wisam Muen, Lena Namaan Salman, Nicholas Freestone & Ali A. Al-Kinani. (2023) Pharmacological treatment strategies of pterygium: Drugs, biologics, and novel natural products. Drug Discovery Today 28:1, pages 103416.
Crossref
Crossref
Ji Eun Lee, Sangyoon Kim, Hyung Keun Lee, Tae-Young Chung, Jae Yong Kim, Chul Young Choi, So Hyang Chung, Dong Hyun Kim, Kyoung Woo Kim, Jin Kwon Chung, Kyu Yeon Hwang, Ho Sik Hwang, Jin Hyoung Kim & Joon Young Hyon. (2022) A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome. Scientific Reports 12:1.
Crossref
Crossref
Yanfang Zhai, Xiaoxiang Zheng, Yunyun Mao, Kai Li, Yanhong Liu, Yuemei Gao, Mengsu Zhao, Rui Yang, Rui Yu & Wei Chen. (2022) Recombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease. International Journal of Molecular Sciences 23:10, pages 5458.
Crossref
Crossref
C: Banu COŞAR, Ayşe Ebru KILAVUZOĞLU, Ali Riza Cenk CELEBİ & Uğur Emrah ALTIPARMAK. (2022) Generic Cyclosporine in the Treatment of Dry Eye Disease. Acibadem Universitesi Saglik Bilimleri Dergisi 13:2.
Crossref
Crossref
A. A. Panov, A. A. Petukhova, Ya. V. Malygin, B. D. Tsygankov & M. A. Kazanfarova. (2022) Adverse ocular effects of neuroleptic therapy: semiotics, pathogenesis and treatment. Russian Ophthalmological Journal 14:4, pages 172-178.
Crossref
Crossref
Rujun Jin, Ying Li, Lan Li, Jonghwa Kim, Hyeon Yoon & Kyung Yoon. (2021) Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities. Experimental and Therapeutic Medicine 22:6.
Crossref
Crossref
Lubna M. Eldesouky, Riham M. El-Moslemany, Alyaa A. Ramadan, Mahmoud H. Morsi & Nawal M. Khalafallah. (2021) Cyclosporine Lipid Nanocapsules as Thermoresponsive Gel for Dry Eye Management: Promising Corneal Mucoadhesion, Biodistribution and Preclinical Efficacy in Rabbits. Pharmaceutics 13:3, pages 360.
Crossref
Crossref
Jeongah ShinChang Rae RhoJoon Young HyonTae-Young ChungKyung Chul YoonChoun-Ki Joo. (2021) A Randomized, Placebo-Controlled Phase II Clinical Trial of 0.01% or 0.02% Cyclosporin A with 3% Trehalose in Patients with Dry Eye Disease. Journal of Ocular Pharmacology and Therapeutics 37:1, pages 4-11.
Crossref
Crossref
Carla S. Medeiros & Marcony R. Santhiago. (2020) Corneal nerves anatomy, function, injury and regeneration. Experimental Eye Research 200, pages 108243.
Crossref
Crossref
Rujun Jin, Ying Li, Lan Li, Dong Hwan Kim, Che Dong Yang, Han Sun Son, Jung Han Choi, Hyeon Jeong Yoon & Kyung Chul Yoon. (2020) Anti‑inflammatory effects of glycine thymosin�β4 eye drops in experimental dry eye. Biomedical Reports.
Crossref
Crossref
Inna A. Riks. (2019) Cyclosporine use in “dry eye” syndrome. Ophthalmology Reports 12:3, pages 75-82.
Crossref
Crossref